Global Aviation Advocacy Coalition

Share this post

GAAC's Open Letter to the Federal Aviation Administration

gaacoalition.substack.com

GAAC's Open Letter to the Federal Aviation Administration

Covid-19 Vaccination and Category 1-3 Medical Certificate Holders

Jun 22, 2022
16
Share this post

GAAC's Open Letter to the Federal Aviation Administration

gaacoalition.substack.com

June 22, 2022

13 GAAC members, lead by US Freedom Flyers, engage the USA’s aviation regulator, the Federal Aviation Administration, with essential questions around the safe conduct of flight operations in the context of Covid-19 policy.

Read the letter (below) and contribute to the dialogue direct with TC via info@faa.gov

Note: Faulty question numbering is a substack artefact.

Gaac Usa Faa 2206
446KB ∙ PDF File
Download
Download


For the attention of:

Billy Nolan, Administrator (Acting)

Bradley Mims, Deputy Administrator

David Boulter, Associate Administrator (Acting), Aviation Safety

Marc Nichols, Chief Counsel

Federal Aviation Agency

800 Independence Ave SW

Washington, DC 20591

June 22nd, 2022

From: Global Aviation Advocacy Coalition gaacoalition@protonmail.com

Sent by email and signed-for letter

Dear Sirs,

Re: Covid-19 Vaccination and Class 1-3 Medical Certificate Holders

The Global Aviation Advocacy Coalition (GAAC) comprises international aviation professionals, medical and scientific expert groups from the UK, USA, Canada, Australia, France, Germany, Austria, Netherlands and Switzerland, as well as passengers. We unite in the the pursuit of safe flying across the globe and so we share and endorse the FAA's goal of ensuring “the safest, most efficient aerospace system in the world” from both consumer and professional perspectives.

As American and international aircrew and citizens who fly within and through American airspace and on American carriers, we write to you to ask the following questions of the Federal Aviation Agency:

  1. Please explain how the Federal Aviation Agency assesses Covid-19 vaccines' suitability for use by Class 1-3 medical certificate holders since their roll out.

  2. Does the Federal Aviation Agency collect reports of Covid-19 vaccine effects, side-effects and severe adverse events (including suspected or proven resultant death) occurring in any Class 1-3 medical holder and if it does please explain how this data is collected?

  3. Is the Federal Aviation Agency aware of any Covid-19 vaccine-induced adverse events in any American Class 1-3 medical certificate holder? If so, how many such events is the Federal Aviation Agency aware of and how does the FAA categorise their severity?

  4. Does the Federal Aviation Agency keep data relating to the numbers of Class 1-3 medical certificates that:

    • are held;

    • temporarily suspended;

    • permanently suspended;

in any given year?

If so, how many years of such data does the Federal Aviation Agency hold?

  1. Holders of Class 1-3 medical certificates are expected to self-report medical issues to the Federal Aviation Agency, except where issues are actually detected during a Federal Aviation Agency medical examination. How and when does the Federal Aviation Agency, via its medical system, become aware of certificate holders' medical issues if they do not self-report those issues to the Federal Aviation Agency?

  2. On an average, per yearly basis, approximately what proportion of all flights that the Federal Aviation Agency is responsible for regulating within American airspace are conducted by multi-person crews and what proportion are conducted by single pilot?

  3. Does the Federal Aviation Agency hold data documenting on a yearly basis passenger and crew medical:

    • incidents;

    • accidents; and

    • diversions of any aircraft inside American airspace and/or on N-registered aircraft globally?

  4. How many Class 1-3 medical certificate holders has the FAA authorised to engage in:

    • any phase 1, 2 or 3 clinical trial for any Covid-19 drug, treatment, therapy, protocol or vaccine; and/or

    • any form of trial, protocol or evaluation of "mix-and-match" Covid-19 booster use e.g. Pfizer vaccination followed by another manufacturer’s vaccine?

We thank you for your anticipated efforts in providing your insight into the above questions and look forward to receiving your reply by email in due course.

Share this post

GAAC's Open Letter to the Federal Aviation Administration

gaacoalition.substack.com
Comments
TopNewCommunity

No posts

Ready for more?

© 2023 GAA Coalition
Privacy ∙ Terms ∙ Collection notice
Start WritingGet the app
Substack is the home for great writing